Src家族激酶是否与伊马替尼和达沙替尼耐药的慢性髓性白血病有关？ - Suppr | 超能文献

Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?

作者信息

Chen Yaoyu

出版信息

Leuk Res. 2011 Jan;35(1):27-9. doi: 10.1016/j.leukres.2010.07.032. Epub 2010 Aug 19.

DOI:10.1016/j.leukres.2010.07.032

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?Src家族激酶是否与伊马替尼和达沙替尼耐药的慢性髓性白血病有关？

Leuk Res. 2011 Jan;35(1):27-9. doi: 10.1016/j.leukres.2010.07.032. Epub 2010 Aug 19.

2

Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.SRC 家族激酶在伊马替尼和达沙替尼耐药慢性髓性白血病患者中的纵向研究。

Leuk Res. 2011 Jan;35(1):38-43. doi: 10.1016/j.leukres.2010.06.030. Epub 2010 Jul 29.

3

Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.伊马替尼耐药后慢性髓性白血病的治疗：二线治疗方案护理指南

Clin J Oncol Nurs. 2009 Oct;13(5):523-34. doi: 10.1188/09.CJON.523-534.

4

Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.伴有e19a2非典型转录本的慢性髓性白血病：早期伊马替尼耐药及对达沙替尼的完全缓解

Cancer Genet Cytogenet. 2010 Sep;201(2):133-4. doi: 10.1016/j.cancergencyto.2010.05.012.

5

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.伏立诺他（辛二酰苯胺异羟肟酸）与达沙替尼（BMS-354825）联合治疗可增强达沙替尼对甲磺酸伊马替尼敏感或甲磺酸伊马替尼耐药的慢性粒细胞白血病细胞的活性。

Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.

6

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.联合使用Abl抑制剂疗法以降低慢性髓性白血病的耐药性：Src/Abl抑制剂与伊马替尼兼容。

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93. doi: 10.1158/1078-0432.CCR-05-0622.

7

Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.达沙替尼：从治疗对伊马替尼耐药或不耐受的慢性髓性白血病患者到治疗新诊断的慢性期慢性髓性白血病患者。

Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.

8

Dasatinib in chronic myelogenous leukemia.达沙替尼治疗慢性粒细胞白血病

N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4.

9

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。

Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.

10

[Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].达沙替尼治疗慢性期慢性髓性白血病的伊马替尼耐药和不耐受患者

Ter Arkh. 2009;81(7):41-6.

引用本文的文献

1

Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.造血细胞激酶（HCK）作为免疫细胞和癌细胞的治疗靶点。

Oncotarget. 2015 Jun 30;6(18):15752-71. doi: 10.18632/oncotarget.4199.

2

Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.Src 家族激酶抑制剂 PP2 对全反式维甲酸或三氧化二砷诱导的急性早幼粒细胞白血病细胞系分化的影响不同。

Cancer Res Treat. 2013 Jun;45(2):126-33. doi: 10.4143/crt.2013.45.2.126. Epub 2013 Jun 30.

3

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.在癌症治疗中靶向Src 家族激酶：将承诺转化为胜利。

Trends Pharmacol Sci. 2012 Mar;33(3):122-8. doi: 10.1016/j.tips.2011.11.002. Epub 2011 Dec 9.